{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:37:35Z","timestamp":1790095055140,"version":"4.0.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized oncology by enhancing antitumor immune responses. However, their use is frequently associated with immune-mediated adverse events, including colitis (ICIs-colitis). This condition shares clinical and histological features with inflammatory bowel diseases (IBD), such as Crohn\u2019s disease (CD) and ulcerative colitis (UC). Emerging evidence highlights the gut microbiota\u2019s role in both ICIs-colitis and IBD pathogenesis. This study aimed to determine whether a distinct microbiota profile, assessed via machine learning, could differentiate ICIs-colitis from IBD and healthy controls (HCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective study was conducted with patients diagnosed with ICIs-colitis, alongside historical cohorts of IBD patients (active and inactive UC\/CD) and HCs. Stool samples were analyzed using 16S rRNA gene sequencing. Diversity metrics (alpha and beta) and differential abundance at multiple taxonomic levels were evaluated. Machine learning techniques, including supervised and unsupervised algorithms, were employed to identify microbiota patterns and signatures distinguishing the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen patients with ICIs-colitis, 40 with UC (20 active, 20 inactive), 34 with CD (14 active, 20 inactive), and 36 HCs were analyzed. Alpha diversity differed between ICI-colitis and UC (P\u2009=\u2009.03) and between ICI-colitis and CD (P\u2009=\u2009.0002), but not versus healthy controls (P\u2009=\u2009.94). Beta diversity showed significant disease-associated clustering among ICI-colitis, UC and CD (PERMANOVA P\u2009&amp;lt;\u2009.001). Differential abundance analyses identified higher Enhydrobacter in ICI-colitis versus IBD and higher Bifidobacterium longum in UC. Machine-learning approaches (sparse partial least squares discriminant analysis, sPLS-DA, and Random Forest) supported group discrimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A unique microbiota signature characterizes ICIs-colitis compared to IBD and HCs. These findings underscore the potential of microbiota profiling and machine learning to aid in diagnosing and managing ICIs-colitis. Future studies should validate these findings in larger, multicenter cohorts, and explore therapeutic implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf376","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T12:57:42Z","timestamp":1763211462000},"source":"Crossref","is-referenced-by-count":2,"title":["Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-8243","authenticated-orcid":false,"given":"Brigida","family":"Barberio","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Patuzzi","sequence":"additional","affiliation":[{"name":"Research & Development Division, EuBiome Srl , Via della Croce Rossa 112 , Padova, Veneto 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9816-4171","authenticated-orcid":false,"given":"Luisa","family":"Bertin","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Facchin","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"De Ruvo","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Gastrointestinal Oncological Surgery, S. Maria del Prato Hospital , Feltre 32032,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bonazzi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"De Barba","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-717X","authenticated-orcid":false,"given":"Alessandro","family":"Dal Maso","sequence":"additional","affiliation":[{"name":"Veneto Institute of Oncology IOV-IRCCS , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-5072","authenticated-orcid":false,"given":"Stefano","family":"Frega","sequence":"additional","affiliation":[{"name":"Veneto Institute of Oncology IOV-IRCCS , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Simionati","sequence":"additional","affiliation":[{"name":"Research & Development Division, EuBiome Srl , Via della Croce Rossa 112 , Padova, Veneto 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sattin","sequence":"additional","affiliation":[{"name":"BMR Genomics Via Redipuglia 22 , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Buda","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Gastrointestinal Oncological Surgery, S. Maria del Prato Hospital , Feltre 32032,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-1502","authenticated-orcid":false,"given":"Fabiana","family":"Zingone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-8940","authenticated-orcid":false,"given":"Angelo Paolo","family":"Dei Tos","sequence":"additional","affiliation":[{"name":"Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova , Padova 35100,","place":["Italy"]},{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova , Padova 35100,","place":["Italy"]},{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Vincenzo","family":"Savarino","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova , Padova 35100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2025121103121142300_oyaf376-B1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2025121103121142300_oyaf376-B2","doi-asserted-by":"crossref","first-page":"800879","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"2025121103121142300_oyaf376-B3","doi-asserted-by":"crossref","first-page":"102440","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor\u2013induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2025121103121142300_oyaf376-B4","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1158\/0008-5472.CAN-16-0448","article-title":"Fine-Tuning cancer immunotherapy: optimizing the gut microbiome","volume":"76","author":"Pitt","year":"2016","journal-title":"Cancer Res"},{"key":"2025121103121142300_oyaf376-B5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the microbiota in immunity and inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"key":"2025121103121142300_oyaf376-B6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nature13279","article-title":"Focused specificity of intestinal TH17 cells towards commensal bacterial antigens","volume":"510","author":"Yang","year":"2014","journal-title":"Nature"},{"key":"2025121103121142300_oyaf376-B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"2025121103121142300_oyaf376-B8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"2025121103121142300_oyaf376-B9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4291\/wjgp.v10.i2.17","article-title":"Immune checkpoint inhibitor-induced diarrhea\/colitis: endoscopic and pathologic findings","volume":"10","author":"Nishida","year":"2019","journal-title":"World J Gastrointest Pathophysiol"},{"key":"2025121103121142300_oyaf376-B10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025121103121142300_oyaf376-B11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ueg2.12485","article-title":"Gut microbiota signatures in inflammatory bowel disease","volume":"12","author":"Vestergaard","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2025121103121142300_oyaf376-B12","doi-asserted-by":"crossref","first-page":"103632","DOI":"10.1016\/j.esmoop.2024.103632","article-title":"A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European Consortium","volume":"9","author":"Lenti","year":"2024","journal-title":"ESMO Open"},{"key":"2025121103121142300_oyaf376-B13","doi-asserted-by":"crossref","first-page":"e13914","DOI":"10.1111\/nmo.13914","article-title":"Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease","volume":"32","author":"Facchin","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"2025121103121142300_oyaf376-B14","doi-asserted-by":"crossref","first-page":"2028366","DOI":"10.1080\/19490976.2022.2028366","article-title":"A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach","volume":"14","author":"Barberio","year":"2022","journal-title":"Gut Microbes"},{"key":"2025121103121142300_oyaf376-B15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2013.07.024","article-title":"Reliability and initial validation of the ulcerative colitis endoscopic index of severity","volume":"145","author":"Travis","year":"2013","journal-title":"Gastroenterology"},{"key":"2025121103121142300_oyaf376-B16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"2025121103121142300_oyaf376-B17","doi-asserted-by":"crossref","first-page":"e105592","DOI":"10.1371\/journal.pone.0105592","article-title":"Development of a prokaryotic universal primer for simultaneous analysis of bacteria and archaea using next-generation sequencing","volume":"9","author":"Takahashi","year":"2014","journal-title":"PLoS One"},{"key":"2025121103121142300_oyaf376-B18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","article-title":"Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2","volume":"37","author":"Bolyen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2025121103121142300_oyaf376-B19","first-page":"e4600","article-title":"GMPR: a robust normalization method for zero-inflated count data with application to microbiome sequencing data","volume-title":"PeerJ","author":"Chen","year":"2018"},{"key":"2025121103121142300_oyaf376-B20","doi-asserted-by":"crossref","first-page":"1001623","DOI":"10.3389\/fimmu.2022.1001623","article-title":"Interaction between gut microbiota and immune checkpoint inhibitor-related colitis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"2025121103121142300_oyaf376-B21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13073-021-00974-z","article-title":"Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma","volume":"13","author":"Usyk","year":"2021","journal-title":"Genome Med"},{"key":"2025121103121142300_oyaf376-B22","doi-asserted-by":"crossref","first-page":"756872","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal microbiome associated with Immune-Related adverse events for patients treated with anti-PD-1 inhibitors, a Real-World study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"2025121103121142300_oyaf376-B23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf376\/65356008\/oyaf376.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf376\/65356008\/oyaf376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf376\/65356008\/oyaf376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:12:20Z","timestamp":1765440740000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf376\/8325123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf376","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,17]]},"article-number":"oyaf376"}}